

La cardiologie interventionnelle

SCA

L Belle Annecy France

La cardiologie interventionnelle

SCA - STEMI

La cardiologie interventionnelle

SCA - STEMI - PPCI

Conflits d'intérêt


- Participation à des symposia :

Médecines company, Lilly, Astra, Abbott, Biotronik...


- Bourses de recherche :

Medtronic , Abbott, Biotronik, Lilly, Boston, Hexacath, Terumo, St Jude ...


PPCI




PPCI



PPCI









Figure 5 Infarct-Related Artery Stent Thrombosis

Two-year cumulative infarct-related artery stent thrombosis (IRA-ST) rate for the total population and according to the existence of large thrombus burden (LTB) or small thrombus burden (STB) at the index procedure.



A Randomized Comparison of Direct Stenting With Conventional Stent Implantation in Selected Patients With Acute Myocardial Infarction

Christophe Loubeyre, MD, Marie-Claude Morice, MD, FESC, FACC, Thierry Lefèvre, MD, FSCAI, FESC, Jean-François Piéchaud, MD, Yves Louvard, MD, Pierre Dumas, MD

Quincy-sous-Sénart, France






Figure 2. In-hospital clinical outcome (numbers indicate percent of events) in both study groups. Open bar = direct stent; solid bar = conventional. Re-MI = recurrent myocardial infarction; TVR = target-vessel revascularization.

PPCI




PPCI




PPCI



PPCI



PPCI




PPCI




PPCI




PPCI



How important is stent sizing?




STEMI case



TAPAS Study – 1 Year

■ death ■ reinfarction ■ death/reinfarction ■ TVR ■ MACE



Vlaar P. et al., *Lancet*, June 7, 2008,
Vol. 371:1915-20

Thrombus Aspiration During Primary Percutaneous Coronary Intervention Improves Myocardial Reperfusion and Reduces Infarct Size

The EXPIRA (Thrombectomy With Export Catheter in Infarct-Related Artery During Primary Percutaneous Coronary Intervention) Prospective, Randomized Trial




Figure 3 Kaplan-Meier 9-Month Event-Free Survival for End Point of Death

Kaplan-Meier analysis shows 9-month event-free survival for the end point of death in the standard percutaneous coronary intervention (S-PCI) treatment group as compared with the Export Medtronic percutaneous coronary intervention (EM-PCI) treatment group.



INFUSE-AMI

A 2x2 Factorial, Multicenter, Prospective,
Randomized Evaluation of Intracoronary Abciximab
and Aspiration Thrombectomy in Patients
Undergoing Primary PCI for Anterior STEMI

Gregg W. Stone, MD

Columbia University Medical Center
NewYork-Presbyterian Hospital
Cardiovascular Research Foundation

ClinicalTrials.gov number:
NCT00976521

INFUSE-AMI Trial

452 pts with anterior STEMI

Anticipated Sx to PCI <5 hrs, TIMI 0-2 flow in prox or mid LAD

Primary PCI with bivalirudin anticoagulation

Pre-loaded with aspirin and
clopidogrel 600 mg or prasugrel 60 mg

Stratified by symptoms to angio <3 vs ≥3 hrs,
and prox vs mid LAD occlusion

R
1:1

Manual aspiration

No aspiration

R
1:1

R
1:1

IC Abcx

No Abcx

IC Abcx


No Abcx

Primary endpoint: Infarct size at 30 days (cMRI)

2° endpoints: TIMI flow, blush, ST-resolution, MACE (30d, 1 yr)

INFUSE-AMI: Infarct size at 30 days*

- Major secondary endpoint -




*Core laboratory assessed. No interaction was present between the 2 randomization groups for the primary 30-day infarct size endpoint (p=0.46)

Infuse AMI

The final word on aspiration in STEMI awaits the ongoing large-scale randomized TOTAL and TASTE trials


PPCI




PPCI



PPCI




PPCI



PPCI




PPCI




PPCI




PPCI



PPCI



PPCI




PPCI




PPCI




PPCI




PPCI




PPCI




PPCI




PPCI




PPCI



PPCI






Adjunctive mechanical devices and **distal embolization**, with ORs and 95% CIs. The size of the data markers (squares) is approximately proportional to the statistical weight of each trial.

A new approach of primary angioplasty for ST-elevation acute myocardial infarction based on minimalist immediate mechanical intervention

Karl Isaaz, Christophe Robin, Alexis Cerisier, Michel Lamaud, Laure Richard, Antoine Da Costa, Mohamed Hassan Sabry, Claude Gerenton




Immediate versus delayed angioplasty in infarct-related arteries with TIMI III flow and ST segment recovery: a matched comparison in acute myocardial infarction patients

Pts referred for primary or rescue PCI with TIMI III flow IRA, ST segment resolution $\geq 70\%$ and thrombus-containing lesion

Before initial diagnostic angiography:

- Aspirin 500 mg IV + 75mg once daily
- Clopidogrel 300 mg loading dose + 75mg once daily
- LWMH (30mg IV bolus + 1mg/kg SC every 12h) or UFH in pts >75y or with Cr.Cl.<30ml/min (60U/kg + infusion of 12U/kg/h)



Nicolas Meneveau
Marie France S ronde
Vincent Descotes-Genon
Joanna Dutheil
Romain Chopard
Fiona Ecarnot
Florent Briand
Yvette Bernard
Fran ois Schiele
Jean-Pierre Bassand

Table 3 Post-procedural angiographic data

	Immediate PCI (<i>n</i> = 39)	Delayed PCI (<i>n</i> = 39)	<i>P</i>
PCI	39 (100%)	35 (90%)	0.04
Direct stenting	20 (51%)	22 (62%)	0.32
Reference diameter post-PCI (mm)	3.08 ± 0.5	3.24 ± 0.6	0.27
MLD post-PCI (mm)	2.63 ± 0.5	2.85 ± 0.6	0.12
% diameter stenosis post-PCI	15.7 ± 8	13.4 ± 7	0.21
TIMI 3 flow	35 (90%)	39 (100%)	0.04
Corrected TIMI frame count	26.5 ± 16	11.8 ± 3.6	0.02
Distal embolisation	7 (18%)	2 (5%)	0.008
No reflow or slow flow	6 (15%)	1 (3%)	0.03
Procedural success	30 (77%)	37 (95%)	0.008

PCI percutaneous coronary intervention, *MLD* minimal lumen diameter

Nicolas Meneveau
Marie France Séronde
Vincent Descotes-Genon
Joanna Dutheil
Romain Chopard
Fiona Ecarnot
Florent Briand
Yvette Bernard
François Schiele
Jean-Pierre Bassand

Table 3 Post-procedural angiographic data

	Immediate PCI (n = 39)	Delayed PCI (n = 39)	P
PCI	39 (100%)	35 (90%)	0.04
Direct stenting	20 (51%)	22 (62%)	0.32
Reference diameter post-PCI (mm)	3.08 ± 0.5	3.24 ± 0.6	0.27
MLD post-PCI (mm)	2.63 ± 0.5	2.85 ± 0.6	0.12
% diameter stenosis post PCI	15.7 ± 8	13.4 ± 7	0.21
TIMI 3 flow	35 (90%)	39 (100%)	0.04
Corrected TIMI frame count	26.5 ± 16	11.8 ± 3.6	0.02
Distal embolisation	7 (18%)	2 (5%)	0.008
No reflow or slow flow	6 (15%)	1 (3%)	0.03
Procedural success	30 (77%)	37 (95%)	0.008

PCI percutaneous coronary intervention, *MLD* minimal lumen diameter

Nicolas Meneveau
Marie France S  ronde
Vincent Descotes-Genon
Joanna Dutheil
Romain Chopard
Fiona Ecartot
Florent Briand
Yvette Bernard
Fran  ois Schiele
Jean-Pierre Bassand

Table 3 Post-procedural angiographic data

	Immediate PCI (n = 39)	Delayed PCI (n = 39)	P
PCI	39 (100%)	35 (90%)	0.04
Direct stenting	20 (51%)	22 (62%)	0.32
Reference diameter post-PCI (mm)	3.08 ± 0.5	3.24 ± 0.6	0.27
MLD post-PCI (mm)	2.63 ± 0.5	2.85 ± 0.6	0.12
% diameter stenosis post-PCI	15.7 ± 8	13.4 ± 7	0.21
TIMI 3 flow	35 (90%)	39 (100%)	0.04
Corrected TIMI frame count	26.5 ± 16	11.8 ± 3.6	0.02
Distal embolisation	7 (18%)	2 (5%)	0.008
No reflow or slow flow	6 (15%)	1 (3%)	0.03
Procedural success	30 (77%)	37 (95%)	0.008

PCI percutaneous coronary intervention, MLD minimal lumen diameter

Nicolas Meneveau
Marie France S  ronde
Vincent Descotes-Genon
Joanna Dutheil
Romain Chopard
Fiona Ecartot
Florent Briand
Yvette Bernard
Fran  ois Schiele
Jean-Pierre Bassand

Table 3 Post-procedural angiographic data

	Immediate PCI (<i>n</i> = 39)	Delayed PCI (<i>n</i> = 39)	<i>P</i>
PCI	39 (100%)	35 (90%)	0.04
Direct stenting	20 (51%)	22 (62%)	0.32
Reference diameter post-PCI (mm)	3.08 ± 0.5	3.24 ± 0.6	0.27
MLD post-PCI (mm)	2.63 ± 0.5	2.85 ± 0.6	0.12
% diameter stenosis post-PCI	15.7 ± 8	13.4 ± 7	0.21
TIMI 3 flow	35 (90%)	39 (100%)	0.04
Corrected TIMI frame count	26.5 ± 16	11.8 ± 3.6	0.02
Distal embolisation	7 (18%)	2 (5%)	0.008
No reflow or slow flow	6 (15%)	1 (3%)	0.03
Procedural success	30 (77%)	37 (95%)	0.008

PCI percutaneous coronary intervention, *MLD* minimal lumen diameter

Nicolas Meneveau
Marie France Séronde
Vincent Descotes-Genon
Joanna Dutheil
Romain Chopard
Fiona Ecarnot
Florent Briand
Yvette Bernard
François Schiele
Jean-Pierre Bassand

Table 3 Post-procedural angiographic data

	Immediate PCI (<i>n</i> = 39)	Delayed PCI (<i>n</i> = 39)	<i>P</i>
PCI	39 (100%)	35 (90%)	0.04
Direct stenting	20 (51%)	22 (62%)	0.32
Reference diameter post-PCI (mm)	3.08 ± 0.5	3.24 ± 0.6	0.27
MLD post-PCI (mm)	2.63 ± 0.5	2.85 ± 0.6	0.12
% diameter stenosis post-PCI	15.7 ± 8	13.4 ± 7	0.21
TIMI 3 flow	35 (90%)	39 (100%)	0.04
Corrected TIMI frame count	26.5 ± 16	11.8 ± 3.6	0.02
Distal embolisation	7 (18%)	2 (5%)	0.008
No reflow or slow flow	6 (15%)	1 (3%)	0.03
Procedural success	30 (77%)	37 (95%)	0.008

PCI percutaneous coronary intervention, *MLD* minimal lumen diameter

Nicolas Meneveau
Marie France Séronde
Vincent Descotes-Genon
Joanna Dutheil
Romain Chopard
Fiona Ecarnot
Florent Briand
Yvette Bernard
François Schiele
Jean-Pierre Bassand



MIMI Study



MIMI - STUDY DESIGN

**PPCI (STEMI < 12 h): TIMI 0 =>
Thromboaspiration => TIMI 3**

**ASA-THIENOPERIDINE
HNF/HBPM-GPI**

N= 140

Double-blind


**Intentional direct
stenting**

**MIMI : Intentional
24-48 h stenting**

1° endpoint: 4-7 Day MRI microvascular obstruction
**2° endpoints: Post procedure TIMI, Blush, ST, artery
diameter, thrombus burden, type of revascularisation.
Recurrent culprit artery occlusion
6 month MACE.**

Total des inclusions : 88 patients

Inclus par centre



Aspirate and wait: deferred stenting during primary angioplasty after prolonged anticoagulation. A single center safety and feasibility study

1143 PPCI



114 Thrombus aspiration → TIMI 3 and ST résolution : STOP




**1-2 weeks of
anticoagulation**


**No MACE
No IRA occlusion
74 stents**



Super MIMI





Super MIMI




MGUARD

Net Protective Stent



MGuard in STEMI - a Meta Analysis



Perfusion with MGuard



	N	TIMI 3	Blush 3	Complete ST res.
Piscione	100	N/A	90%	90%
Dudek	60	90%	73%	61%
Weerackody	51	100%	N/A	N/A
Apro	100	96%	N/A	N/A
Average	311	95% (n=211)	83% (n=160)	79% (n=160)

MGuard vs. standard care


Perfusion results



* Giuseppe De Luca; European Heart Journal (2008) 29, 3002–3010, TAPAS study, *N Engl J Med* 2008;358:557-67, MGuard meta-analysis.

** No direct comparison performed between MGuard and the other therapy strategies

MGuard in the ESC Guidelines (2010)



In the 2010 European Guidelines on Myocardial revascularization, mesh-based protection, is now recommended for use:



“Mesh-based protection may be considered for PCI of highly thrombotic or SVG lesions” (class IIb/c recommendation)

IVUS-guided stent implantation may be considered for unprotected left main PCI.	IIb	C
Mesh based protection may be considered for PCI of highly thrombotic or SVG lesions	IIb	C
For PCI of unstable lesions, intracoronary nitroglycerine or other vasodilators may be considered for pharmacological	...	-


*European Heart Journal (31):2051-2555 -doi:10.1093/eurheartj/ehq277

The Master Trial Design


Randomized Controlled Trial



The Self-Apposing Stent for varying anatomy



The Sizing Dilemma in bifurcations



Picture from STENTYS OPEN I bifurcation trial

Conclusion

- **Thromboaspiration prudente**
- **Filtres**
- **M'Guard**
- **MIMI**
- **Super MIMI**
- **Drogues : Antiagregants Pq oraux, GPI, Cyclosporine**